Teva Pharmaceutical Industries (TEVA) P/S ratio
Teva Pharmaceutical Industries (TEVA) trades at 2.9× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 2.1×. That is 39.6% higher than the 1.5× of fiscal 2024. Figures as of 18 Nov 2026, 09:52 UTC, from the company's filings with the SEC and Yahoo Finance.
Key facts
- P/S ratio today
- 2.9×
- P/S ratio, fiscal 2025
- 2.1×
- Change on fiscal 2024
- +39.6%
- Highest on record
- 7.8×fiscal 2016
- Lowest on record
- 0.6×fiscal 2021
- Fiscal years on record
- 192007–2025
Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.
Teva Pharmaceutical Industries P/S ratio, in more detail
Today's figure is 36.6% above the fiscal 2025 year-end.
Across the 19 fiscal year-ends on record (2007–2025), the highest was 7.8× in fiscal 2016 and the lowest 0.6× in fiscal 2021. Today's P/S ratio is higher than at 68% of the 19 fiscal year-ends on record; their median is 1.7×.
P/S ratio at each fiscal year-end
The last point is today's figure; the others are fiscal year-ends.
Teva Pharmaceutical Industries P/S ratio, year by year
| Fiscal year | P/S ratio | Change | Year ended | Share price at year-end | Revenue per share |
|---|---|---|---|---|---|
| Today | 2.9× | — | $42.62 | — | |
| 2025 | 2.1× | 39.6% up | $31.21 | $14.84 | |
| 2024 | 1.5× | 104.4% up | $22.04 | $14.63 | |
| 2023 | 0.7× | 8.7% up | $10.44 | $14.16 | |
| 2022 | 0.7× | 21.5% up | $9.12 | $13.45 | |
| 2021 | 0.6× | 12.0% down | $8.01 | $14.34 | |
| 2020 | 0.6× | 0.2% up | $9.65 | $15.21 | |
| 2019 | 0.6× | 26.5% down | $9.80 | $15.48 | |
| 2018 | 0.9× | 2.2% down | $15.42 | $17.90 | |
| 2017 | 0.9× | 88.7% down | $18.95 | $21.51 | |
| 2016 | 7.8× | 169.5% up | $36.25 | $4.66 | |
| 2015 | 2.9× | 18.6% up | $65.64 | $22.75 | |
| 2014 | 2.4× | 45.1% up | $57.51 | $23.63 | |
| 2013 | 1.7× | 4.5% up | $40.08 | $23.90 | |
| 2012 | 1.6× | 18.5% down | $37.34 | $23.27 | |
| 2011 | 2.0× | 33.9% down | $40.36 | $20.51 | |
| 2010 | 3.0× | 4.6% down | $52.13 | $17.50 | |
| 2009 | 3.1× | 0.8% down | $56.18 | $17.99 | |
| 2008 | 3.1× | 23.2% down | $42.57 | $13.52 | |
| 2007 | 4.1× | — | $46.48 | $11.33 |
Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.
How it is calculated
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end.
How to read it
It prices each unit of sales and still works when there is no profit; what counts as high depends on the margin those sales earn.
P/S ratio at health care companies of similar size
| Company | P/S ratio |
|---|---|
| Medline MDLN | 1.7× |
| Humana HUM | 0.4× |
| Agilent Technologies A | 7.0× |
| Teva Pharmaceutical Industries TEVA | 2.9× |
| BeOne Medicines ONC | 8.8× |
| Waters WAT | 27.9× |
Today's market value divided by revenue for the latest fiscal year. A company whose statements are in another currency than its shares is left out.
Teva Pharmaceutical Industries, figure by figure
- Teva Pharmaceutical Industries market cap
- Teva Pharmaceutical Industries revenue
- Teva Pharmaceutical Industries earnings
- Teva Pharmaceutical Industries earnings per share (EPS)
- Teva Pharmaceutical Industries P/E ratio
- Teva Pharmaceutical Industries P/B ratio
- Teva Pharmaceutical Industries free cash flow
- Teva Pharmaceutical Industries operating margin
- Teva Pharmaceutical Industries dividend
- Teva Pharmaceutical Industries shares outstanding
- Teva Pharmaceutical Industries total debt
- Teva Pharmaceutical Industries cash on hand
- Teva Pharmaceutical Industries total assets
- Teva Pharmaceutical Industries return on equity (ROE)
- Teva Pharmaceutical Industries return on invested capital (ROIC)
Teva Pharmaceutical Industries (TEVA) overview: price, valuation and scorecardAll health care companies by market value
Teva Pharmaceutical Industries P/S ratio: questions and answers
What is Teva Pharmaceutical Industries's P/S ratio?
Teva Pharmaceutical Industries (TEVA) trades at 2.9× its revenue per share for fiscal 2025. At the end of fiscal 2025 (December 31, 2025) its P/S ratio was 2.1×. That is 39.6% higher than the 1.5× of fiscal 2024.
Is Teva Pharmaceutical Industries's P/S ratio high or low compared with its own history?
Today's P/S ratio is higher than at 68% of the 19 fiscal year-ends on record; their median is 1.7×.
What are the highest and lowest P/S ratio figures on record for Teva Pharmaceutical Industries?
Across the 19 fiscal year-ends on record (2007–2025), the highest was 7.8× in fiscal 2016 and the lowest 0.6× in fiscal 2021.
How is Teva Pharmaceutical Industries's P/S ratio calculated?
The P/S ratio is the share price divided by revenue per share — the same thing as market value divided by revenue — taken at each fiscal year-end. For Teva Pharmaceutical Industries it is on record here for 19 fiscal years, 2007 to 2025.
Share prices are Yahoo Finance's monthly closes: a fiscal year-end is paired with the close of the month it falls in, and today's quote may be delayed. Fiscal years are named for the calendar year they end in.
Learn: P/S ratio
All stocks guides →- P/E ratio explained: what a high or low figure means
The price-to-earnings (P/E) ratio is a share's price divided by its earnings per share. A stock at $100 earning $5 a share has a P/E of 20: buyers pay $20 for each dollar of yearly profit. A high P/E usually means the market expects profit to grow; a low one can mean doubt, not a bargain.
- Revenue vs earnings vs free cash flow: what each tells you
Revenue is everything a company sold in a period. Earnings, or net income, is what remains after every cost, interest and tax. Free cash flow is the cash operations brought in minus spending on long-lived assets. Revenue shows size and demand, earnings show profitability, and free cash flow shows how much cash the business can actually hand out.
- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
Cite this page
Funkfolio, “Teva Pharmaceutical Industries (TEVA) P/S ratio”, data as of 18 November 2026. https://funkfolio.com/stock/TEVA/ps-ratio
Underlying data: the company's filings with the SEC and Yahoo Finance.